(NASDAQ: GERN) Geron's forecast annual revenue growth rate of 38.31% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.9%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Geron's revenue in 2026 is $196,115,000.On average, 7 Wall Street analysts forecast GERN's revenue for 2026 to be $153,054,073,977, with the lowest GERN revenue forecast at $143,854,663,210, and the highest GERN revenue forecast at $161,823,665,692. On average, 7 Wall Street analysts forecast GERN's revenue for 2027 to be $223,647,041,956, with the lowest GERN revenue forecast at $201,052,673,252, and the highest GERN revenue forecast at $278,407,272,297.
In 2028, GERN is forecast to generate $341,892,187,884 in revenue, with the lowest revenue forecast at $274,866,076,520 and the highest revenue forecast at $506,455,148,134.